Se le puede derrotar al
#COVID19
aun teniendo
#Cancer
. Estoy orgullosísimo del enorme trabajo de todos los compañeros del
@MDAnderson_ES
. Claro que se puede!!!! 💪🏼👏👏👏
@_SEOM
🗣️If you are a fellow, oncologist or work in the pharma industry and want to improve your oral communication skills and make effective presentations, you just have to watch
@montypal
#ESMO22
presidential session discussion on loop. 🎩Hats off!!
@OncoAlert
WOW 😮 Es lo único que puedo decir después de haber tenido la suerte de visitar el nuevo CTIC liderado por
@AndresFCardonaZ
y la Dra Franco en Bogotá 🇨🇴. IMPRESIONANTE!!!! Ojalá en España tuviésemos centros de cáncer así. Apuesto: referente mundial en 5 años.
#envidiasana
EV302 IS POSITIVE!!!!!!! 🥂🍾Amazing news for Urothelial Cancer field!!!! Congratulations to my friend
@tompowles1
and the rest of the team!!!!!
@OncoAlert
@GuardConsortium
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and…
I don’t know about you, but I think it was the most impactful and touching heart ❤️ plenary session I’ve ever been. We’ll remember
#ESMO23
for long time.
Even better we you can enjoy together with friends
@drfernandomaluf
@SoaresAndrey
Amazing presentation by
@tompowles1
and…
I don't have enough words to describe yesterday's day. I can’t be more grateful and happy. Thank you very much
#ESMO19
for giving me the opportunity to present my study on
#BLCSAM
🙋♂️GU friends, don't make plans for Saturday21st, Sunday 22nd and Monday 23rd of October... At least 4 phase 3 potentially practice changing trials will be presented at
#ESMO2023
. Congratulations to all the
@myESMO
team for such exciting program. Can't wait to seeing the data and…
CheckMate901 is positive👏Awesome news for metastatic UC pts!!!! First time anything beats CISGEM for OS in all patients!!! Hopefully EV302 will come next. Why KN361 & IM130 were not consistent?
@OncoAlert
@GuardConsortium
@urotoday
Me siento emocionado con este nuevo reto. Para mi
#ESMO19
supone exponer delante de diferentes profesionales del sector mi estudio sobre
#BLCSAM
. Soy consciente de la responsabilidad que tengo entre manos. Agradecer la confianza que se ha puesto en mi. Vamos a por todas
#ESMO19
Súper orgulloso ☺️de haber presentado en el congreso americano
@ASCO
#GU24
el estudio
#CABATEN
representando a muchos amigos investigadores en
#tumoresNeuroendocrinos
🦓 en España.
@GrupoGetne
es referente en este ámbito y contribuye al conocimiento de entidades tan poco…
🔘 Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy
#bladdercancer
@OncoAlert
@IJROBP
🎯EV 302 summary:
📌PFS 12.5 mo vs 6.3 mo HR 0.45
📌OS 31.5 mo vs 16.1 mo HR 0.47
📌ORR was 67.7% and 44.4%
Everything favored Enfortumab vedotin + Pembro arm
I can’t wait to see the data, particularly subgroup analysis by elegibilty to cisplatin and…
#ESMO21
Any better place for the final check of the presentation? 🤔 Pity that down there the atmosphere is not like a normal congress we are use to, but enormous effort from
@myESMO
staff to accommodate everything and keep everyone safe 🙏
My thoughts about THOR Cohort 2 at
#ESMO23
:
📌 IO should be offered before than FGFR inhibitors in the sequence strategy to manage advanced urothelial tumors.
Higher responses may not compensate the lack of impact in OS and toxicity profile
📌 If EV-Pembro becomes standard in…
🙄 Dear members of the GU community. Let's see if someone can give me some advice how to explain to medical school students the data on PD1/L1 inhibitors in adjuvant RCC and UC.
It's for a friend 😳
@OncoAlert
@GuardConsortium
I leave them there together
👇👇👇👇👇👇👇👇👇👇
Wonderful graph by
@shilpaonc
and cols. at
showing crystal clear the differences in the profile of patients with
#urothelial
carcinoma recruited in large clinical trials vs real-practice. I'm wondering if we can really extrapolate the data?
@OncoAlert
👋🏻 Hey!!!
@neerajaiims
Look where I am 😜 They are still missing you and asking for you to come back!!!!! Here they admire me just for knowing you 😂😂😂 That says how big and humble you are!!!!!
@OncoAlert
🎉 Os estoy muy agradecido, valoro mucho teneros a todos aquí. Así que seguiré intentado hacer que el tiempo que me dedicáis valga la pena, compartiendo noticias y artículos de
#oncolog
ía, así como interactuando con vosotros. Gracias🙏
No words 😶 to describe the feeling at
#ESMO22
presidential session
@DrChoueiri
touching everybody hearts and
@montypal
delivering one of the best ever discussion in RCC. Thank you folks!!
@OncoAlert
⚡️ Immunotherapy transformed cancer care, but not all respond. This review examines current successes, challenges, and future prospects when combining radiotherapy with immunotherapy
#Immunotherapy
#radiotherapy
Precision Medicine is a reality in
#ThyroidCancer
🦋
Selective RET inhibitors are now a new option for patients
@aecat_es
I humbly suggest you read this work we have done in thanks to the coordination of
@Ja_Capdevila
and other friends.
@GrupoGetne
#ESMO23
THOR-2 data were brilliantly presented by
@JimCatto
Huge and significant data with erdafitinib in NMIBC with FGFR2/3
mut/fus tumors that failed to prior BCG.
📌 A major issue: only 76 of the 240 pre-planned patients were recruited
Would it be enough to change…
⚡️ Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC)
#neuroendocrinecancer
@TheLancet
🛫Vuelta a casa con buenas sensaciones por haber intentado aportar nuestro granito de arena para seleccionar mejor los tratamientos para los pacientes con
#c
áncerdevejiga metastásico.
Muchas gracias a
@myesmo
,
@_SEOM
y a mis compañeros de
@MDAnderson_ES
🙏🏻
#ESMO22
🔘 Phase 1 Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
#bladdercancer
#GU23
@ASCO
Da vértigo. No solo mirar hacia atrás en el asiento, sino mirar atrás en el tiempo y saber que después de tantas semanas de preparación, hoy a las 17:48h podré contároslo todo. Espero veros entre todas esas cabezas ¡Vamos
#ESMO19
!
⚡️ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
#BladderCancer
#Immunotherapy
@JCO_ASCO
Enrique Grande, jefe de oncología del MD Anderson: "El estudio del equipo de Joan Massagué promete cambiar la manera en la que hacemos frente al cáncer"
#GU22
now with perspective ☺️... Did you notice the terrific piece of work presented by
@shilpaonc
and her team at
@CleClinicUro
😱 Seems that TMB>10 is better to correlate with OS than PDL1. Should we revise the old and current studies in urothelial tumors?
@OncoAlert
🔘 Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed?
#UrothelialCarcinoma
#bladdercancer
It’s happening!!!! 😍😍
@neerajaiims
shining at
#GU24
podium. The CONTACT-02 is a great trial in mCRPC that hopefully with a longer follow up and OS improvement may impact in daily life of many patients. Huge congrats to the big plethora of coauthors including the master…
Warming up for
#ESMO23
!!!
Amazing Brazilian group 🇧🇷 sharing experiences with us at
@MDAnderson_ES
I love your pro activity mates!!!! Lovely interaction and discussion. Safe travels to all of you coming to Madrid!!!!!
@OncInfo
@OncoAlert
@myESMO
What else we should ask for a combo in 1st line mRCC?
#CheckMate9ER
comes strong to this field. Huge Congrats to
@DrChoueiri
and cols. 🍾 Still a debate on Good Risk and if 8 vs 11% of CRs makes a difference
#ESMO20
By the way, if patient progress what is left?
Important results from
#Cabopoint
trial just released by
@AlbigesL
with daily practice implications at
#GU23
@ASCO
Cabozantinib can rescue patients with mRCC that have failed in less than 6 months to standard 1st line doublet. Huge congrats!!!!🥂🍾
Today, our patients with metastatic
#urothelialcancer
have another option for treatmt. Molecularly selected pts by FGFR3/2 gene alt have the opportunity to receive a driven TKI. Congrats for this achievement at THOR trial & thanks to
@y_loriot
for such a brilliant talk
#ASCO23
Querido
@OncoNerd
: te pudiera admirar como médico, como oncólogo, como investigador, como líder de grupo, como empresario, como sabio, como tenaz, cómo valiente, como ingenioso, cómo brillante en humor negro (qué me encanta), como padre, como hermano, como fotógrafo y hasta como…
Nos visitaron hoy en Astorga los doctores Enrique Grande y Fernando Lista, oncólogo y urólogo oncólogo del MD Anderson de Madrid. Una sesión interactiva, multidisciplinaria, sobre cáncer de próstata metastásico resistente a la castración. Aprendí y disfruté mucho. Gracias!
🗣️ESMO guidelines on Renal Cell Carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis
@myESMO
@Annals_Oncology
Warming up for this evening Educational Session on High-Risk RCC and Urothelial tumors with my favorite co-chair
@ERPlimackMD
So thankful to
#ESMO22
to have this privilege
“Today we saw the first study to show statistically significant improvement in survival in the adjuvant setting of kidney cancer”
@DrChoueiri
dixit
#GU24
will be remembered because of this
Huge congrats Toni for leading the path✊
@oncoalert
Amazing and extremely smart discussion by
@PBarataMD
about the updated & challenging landscape in adjuvant high-risk RCC
#GU24
Pedro, You deserve a trophy 🏆!!!!
Big congrats!!!! By the way, I loved the mention to
@BourlonMaite
😜
@OncoAlert
🗞️🏃♂️🏃♀️ Este análisis sobre la relación entre actividad física y
#c
áncer ofrece nuevas pistas sobre la cantidad de actividad física necesaria para reducir el riesgo de contraer varios tipos de cáncer.
@ASCO_pubs
At
#ESMO23
we have realized that
#PrecisionMedicine
is reaching the field of non-muscle invasive bladder cancer.
@tonivilaseca
did a wonderful presentation about very promising and encouraging data with the new intravesical device TAR-210 releasing erdafitinib inside the bladder…